Related Experiment Video

Updated: Jun 2, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.0K

Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E Activity

Emilio L Cárdenas1, Rachel L O'Rourke1, Arya Menon1

  • 1Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.

ACS Medicinal Chemistry Letters
|January 15, 2025
PubMed

Insights

Researchers developed new cap analogue prodrugs that target eukaryotic translation initiation factor 4E (eIF4E). These compounds show anticancer activity in melanoma cells with BRAF V600E mutations, offering a potential new therapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Dysregulated protein production via translation is crucial for cancer development.
  • Eukaryotic translation initiation factor 4E (eIF4E) controls cap-dependent translation and is often overexpressed in cancers.
  • eIF4E is a validated therapeutic target due to its role in promoting tumor growth and survival.

Purpose of the Study:

  • To design and synthesize novel, second-generation cap analogue prodrugs.
  • To inhibit the interaction between eIF4E and the mRNA cap structure.
  • To evaluate the anticancer efficacy of these new compounds in BRAF V600E mutant melanoma models.

Main Methods:

  • Design and synthesis of second-generation cap analogues with modified N-9-substituted linkers.
  • Evaluation of cell permeability and inhibitory activity against eIF4E.
  • Assessment of anticancer effects in BRAF V600E mutant melanoma cell lines.

Main Results:

  • Successful design and synthesis of novel cap analogues.
  • Demonstrated anticancer activity of the new compounds in BRAF V600E mutant melanoma cells.
  • Identification of promising candidates for further therapeutic development.

Conclusions:

  • Second-generation cap analogues with alternative N-9-substituted linkers are effective anticancer agents.
  • These compounds represent a promising therapeutic strategy targeting eIF4E in BRAF V600E mutant melanoma.
  • Further investigation is warranted to explore their clinical potential.

More Related Videos

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions10:40

Analysis of Cap-binding Proteins in Human Cells Exposed to Physiological Oxygen Conditions

Published on: December 28, 2016

7.8K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

Related Concept Videos

Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
30.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K